Chemotherapy-induced CDA expression renders resistant non-small cell lung cancer cells sensitive to 5′-deoxy-5-fluorocytidine (5′-DFCR)

Abstract Background Pemetrexed (MTA) plus cisplatin combination therapy is considered the standard of care for patients with advanced non-small-cell lung cancer (NSCLC). However, in advanced NSCLC, the 5-year survival rate is below 10%, mainly due to resistance to therapy. We have previously shown t...

Full description

Bibliographic Details
Main Authors: Yanyun Gao, Philipp Zens, Min Su, Camila Anna Gemperli, Haitang Yang, Haibin Deng, Zhang Yang, Duo Xu, Sean R. R. Hall, Sabina Berezowska, Patrick Dorn, Ren-Wang Peng, Ralph Alexander Schmid, Wenxiang Wang, Thomas Michael Marti
Format: Article
Language:English
Published: BMC 2021-04-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Online Access:https://doi.org/10.1186/s13046-021-01938-2